First use of investigational antiviral drug pocapavir (V-073) for treating neonatal enteroviral sepsis

Sanet Torres-Torres; Angela L. Myers; J. Michael Klatte; Eric E. Rhoden; M. Steven Oberste; Marc S. Collett; Russell J. McCulloh

doi:10.1097/INF.0000000000000497

First use of investigational antiviral drug pocapavir (V-073) for treating neonatal enteroviral sepsis

Sanet Torres-Torres, Angela L. Myers, J. Michael Klatte, Eric E. Rhoden, M. Steven Oberste, Marc S. Collett, Russell J. McCulloh

Research output: Contribution to journal › Article › peer-review

19 Scopus citations

Abstract

Neonatal enteroviral sepsis is a potentially fatal condition. Perinatally acquired infection and severe coagulopathy can be associated with a poor clinical outcome, and antiviral therapy is currently unavailable. Pocapavir (V-073) is an investigational drug candidate being developed for poliovirus indications, but also has variable antiviral activity against nonpolio enteroviruses. We describe the first use of pocapavir in treating a case of severe neonatal enteroviral sepsis due to Coxsackievirus B3.

Original language	English (US)
Pages (from-to)	52-54
Number of pages	3
Journal	Pediatric Infectious Disease Journal
Volume	34
Issue number	1
DOIs	https://doi.org/10.1097/INF.0000000000000497
State	Published - 2015
Externally published	Yes

Keywords

Coxsackievirus
Neonatal enterovirus infection
Pocapavir

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Microbiology (medical)
Infectious Diseases

Access to Document

10.1097/INF.0000000000000497

Cite this

First use of investigational antiviral drug pocapavir (V-073) for treating neonatal enteroviral sepsis. / Torres-Torres, Sanet; Myers, Angela L.; Klatte, J. Michael; Rhoden, Eric E.; Oberste, M. Steven; Collett, Marc S.; McCulloh, Russell J.

In: Pediatric Infectious Disease Journal, Vol. 34, No. 1, 2015, p. 52-54.

Research output: Contribution to journal › Article › peer-review

@article{b3d594bb4f0f4df4a489d426225ff970,

title = "First use of investigational antiviral drug pocapavir (V-073) for treating neonatal enteroviral sepsis",

abstract = "Neonatal enteroviral sepsis is a potentially fatal condition. Perinatally acquired infection and severe coagulopathy can be associated with a poor clinical outcome, and antiviral therapy is currently unavailable. Pocapavir (V-073) is an investigational drug candidate being developed for poliovirus indications, but also has variable antiviral activity against nonpolio enteroviruses. We describe the first use of pocapavir in treating a case of severe neonatal enteroviral sepsis due to Coxsackievirus B3.",

keywords = "Coxsackievirus, Neonatal enterovirus infection, Pocapavir",

author = "Sanet Torres-Torres and Myers, {Angela L.} and Klatte, {J. Michael} and Rhoden, {Eric E.} and Oberste, {M. Steven} and Collett, {Marc S.} and McCulloh, {Russell J.}",

year = "2015",

doi = "10.1097/INF.0000000000000497",

language = "English (US)",

volume = "34",

pages = "52--54",

journal = "Pediatric Infectious Disease Journal",

issn = "0891-3668",

publisher = "Lippincott Williams and Wilkins",

number = "1",

}

TY - JOUR

T1 - First use of investigational antiviral drug pocapavir (V-073) for treating neonatal enteroviral sepsis

AU - Torres-Torres, Sanet

AU - Myers, Angela L.

AU - Klatte, J. Michael

AU - Rhoden, Eric E.

AU - Oberste, M. Steven

AU - Collett, Marc S.

AU - McCulloh, Russell J.

PY - 2015

Y1 - 2015

N2 - Neonatal enteroviral sepsis is a potentially fatal condition. Perinatally acquired infection and severe coagulopathy can be associated with a poor clinical outcome, and antiviral therapy is currently unavailable. Pocapavir (V-073) is an investigational drug candidate being developed for poliovirus indications, but also has variable antiviral activity against nonpolio enteroviruses. We describe the first use of pocapavir in treating a case of severe neonatal enteroviral sepsis due to Coxsackievirus B3.

AB - Neonatal enteroviral sepsis is a potentially fatal condition. Perinatally acquired infection and severe coagulopathy can be associated with a poor clinical outcome, and antiviral therapy is currently unavailable. Pocapavir (V-073) is an investigational drug candidate being developed for poliovirus indications, but also has variable antiviral activity against nonpolio enteroviruses. We describe the first use of pocapavir in treating a case of severe neonatal enteroviral sepsis due to Coxsackievirus B3.

KW - Coxsackievirus

KW - Neonatal enterovirus infection

KW - Pocapavir

UR - http://www.scopus.com/inward/record.url?scp=84926217187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926217187&partnerID=8YFLogxK

U2 - 10.1097/INF.0000000000000497

DO - 10.1097/INF.0000000000000497

M3 - Article

C2 - 25229269

AN - SCOPUS:84926217187

VL - 34

SP - 52

EP - 54

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

SN - 0891-3668

IS - 1

ER -

First use of investigational antiviral drug pocapavir (V-073) for treating neonatal enteroviral sepsis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this